Treatments for stage C liver cancer
Targeted therapy @(Model.HeadingTag)>
Targeted therapy is the standard treatment for stage C liver cancer. It uses drugs to treat specific molecules (such as proteins) on cancer cells or inside them. By targeting these molecules, the drugs stop the growth and spread of cancer cells while limiting harm to normal cells. The targeted therapy drugs used for stage C liver cancer are:
- sorafenib (Nexavar)
- lenvatinib (Lenvima)
- regorafenib (Stivarga)
- cabozantinib (Cabometyx)
Immunotherapy helps to strengthen or restore the immune system's ability to find and destroy cancer. You may be offered nivolumab (Opdivo) or pembrolizumab (Keytruda) if you have already had treatment with sorafenib or are unable to take sorafenib or other treatments. Nivolumab and pembrolizumab may not be covered by all provincial health plans.
Radiation therapy @(Model.HeadingTag)>
If you are not well enough to have targeted therapy or immunotherapy, you may be offered external radiation therapy. This treatment can help relieve pain caused by advanced liver cancer (called palliative treatment), such as when cancer spreads to the bones.
Clinical trials @(Model.HeadingTag)>
American Cancer Society. Liver Cancer. 2015: http://www.cancer.org/acs/groups/cid/documents/webcontent/003114-pdf.pdf.
Bruix J, Sherman M. AASLD Practice Guideline: Management of hepatocellular carcinoma: an update. 2010: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer . EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2012.
National Cancer Institute. Adult Primary Liver Cancer Treatment (PDQ®) Health Professional Version. 2015: http://www.cancer.gov/cancertopics/pdq/treatment/adult-primary-liver/HealthProfessional/page1/AllPages.
National Comprehensive Cancer Network (NCCN). Hepatobiliary Cancers Version 2.2015. 2015: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, et al . Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Current Oncology. 2011: http://www.current-oncology.com/index.php/oncology/article/view/952/737.